CAMBRIDGE, Mass. and GOSSELIES, Belgium, July 23, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today
– Matthew Gall joins as Chief Financial Officer – Dr Yvonne McGrath joins as Vice President of R&D – Philippe Brantegem joins as Vice President of Human Resources Cambridge, MA and Gosselies, Belgium – June 9, 2020 – iTeos Therapeutics Inc., a clinical-stage biopharmaceutical company
Cambridge, MA and Gosselies, Belgium – June 1, 2020 – iTeos Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, announced today the appointment of Ann D.
- Proceeds support advancing clinical development of next-generation cancer immunotherapies targeting A 2A adenosine receptor and anti-TIGIT immune checkpoint - - Oversubscribed round co-led by new investors RA Capital Management and Boxer Capital - - New investors Janus Henderson Investors, RTW
btn News Archive
Disclaimer. This page contains express or implied forward-looking statements, which are based on current expectations of management. These statements relate to, among other things, our expectations regarding management’s plans, objectives, and strategies. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward looking statements. iTeos assumes no obligation to update any forward-looking statements [on this page/in this press release] in the event of changing circumstances or otherwise, and such statements are current only as of the date they are made.